Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 3
1948 4
1949 1
1953 2
1958 1
1965 2
1966 1
1967 4
1969 2
1970 2
1971 1
1972 2
1973 3
1974 3
1975 5
1976 5
1977 4
1978 6
1979 9
1980 12
1981 10
1982 15
1983 25
1984 21
1985 24
1986 16
1987 18
1988 10
1989 15
1990 11
1991 13
1992 14
1993 13
1994 15
1995 20
1996 15
1997 10
1998 5
1999 6
2000 16
2001 10
2002 17
2003 16
2004 11
2005 14
2006 24
2007 14
2008 23
2009 23
2010 39
2011 52
2012 33
2013 47
2014 48
2015 49
2016 49
2017 74
2018 78
2019 54
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

962 results
Results by year
Filters applied: . Clear all
Page 1
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
Petrelli F, Ghidini A, Pedersini R, Cabiddu M, Borgonovo K, Parati MC, Ghilardi M, Amoroso V, Berruti A, Barni S. Petrelli F, et al. Breast Cancer Res Treat. 2019 Apr;174(3):597-604. doi: 10.1007/s10549-019-05133-y. Epub 2019 Jan 18. Breast Cancer Res Treat. 2019. PMID: 30659432 Review.
Enasidenib for the treatment of acute myeloid leukemia.
Dugan J, Pollyea D. Dugan J, et al. Expert Rev Clin Pharmacol. 2018 Aug;11(8):755-760. doi: 10.1080/17512433.2018.1477585. Epub 2018 Jul 24. Expert Rev Clin Pharmacol. 2018. PMID: 29770715 Review.
A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
Sekimizu M, Osumi T, Fukano R, Koga Y, Kada A, Saito AM, Mori T. Sekimizu M, et al. Acta Med Okayama. 2018 Aug;72(4):431-436. doi: 10.18926/AMO/56184. Acta Med Okayama. 2018. PMID: 30140094 Free article. Clinical Trial.
Crizotinib-induced simultaneous multiple cardiac toxicities.
Oyakawa T, Muraoka N, Iida K, Kusuhara M, Kawamura T, Naito T, Takahashi T. Oyakawa T, et al. Invest New Drugs. 2018 Oct;36(5):949-951. doi: 10.1007/s10637-018-0605-x. Epub 2018 May 2. Invest New Drugs. 2018. PMID: 29717400
Enasidenib: First Global Approval.
Kim ES. Kim ES. Drugs. 2017 Oct;77(15):1705-1711. doi: 10.1007/s40265-017-0813-2. Drugs. 2017. PMID: 28879540 Review.
Assessment of the efficacy and safety of fampridine.
Mejuto B, Castellano P, Castro C, López LM. Mejuto B, et al. Farm Hosp. 2017 Mar 1;41(2):283-291. doi: 10.7399/fh.2017.41.2.10615. Farm Hosp. 2017. PMID: 28236802 Free article. English.
962 results
Jump to page
Feedback